SBIR/STTR Research Award

SBIR Phase I:Localized and Sustained Antibiotic Delivery For Treatment of Periprosthetic Joint Infection (PJI) in Arthroplasty Patients

Award identifier 65737917a2fae56c27a5c3ebd09718c632eda9e55ff209476352b4a641a7a0feAwarding agency National Science Foundation

Award amount

$255,247

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Reselute, Inc.
Proposal award date
2022-02-15
Contract end date
2023-06-30
UEI
JBMRHJGSMFD6
Solicitation number
NSF 21-562
Topic code
MD

Research abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is develop an innovative medical technology for localized and sustained antibiotic treatment in the case of periprosthetic joint infection (PJI). The proposed activities may result in commercialization of an implant with novel reservoir technology to be placed at the infected site, and which will locally deliver antibiotics to eradicate the infection. This solution may improve patient care as well as reduce costs associated with treatment of infection. The development of an implantable, antibiotic-eluting orthopedic spacer which enables patients to return to ambulatory conditions while providing sustained, appropriate, anti-infection resistance for a sustained duration could benefit patients and reduce medical costs. The proposed product seeks to reduce infections and reduce the need for surgical revision and significant antibiotic treatments. If successful, this technology will reduce the burden associated with unresolved infections and avoid amputations.This team will design, develop, and validate the proof of concept for an orthopedic spacer. The system will be 3-D printed using a novel porous medium capable of controlled antibiotic elution.The product will be tested using benchtop mechanical testing and in vitro studies of implanted system viability and controlled elution. The objectives include a study of the prototype's ability to meet design criteria for mechanical performance, as well as a demonstration of a superior antibiotic elution profile over an extended-release period. The mechanical testing to be performed include load, stress, and cycle testing within current standards, in conjunction with in vitro laboratory elution testing of the specified antibiotic substance over a sustained duration of time (up togreater than 180 days).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $1,568,530. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: National Science Foundation, Department of Health and Human Services

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.